{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T11:57:16Z","timestamp":1790510236575,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,24]],"date-time":"2019-04-24T00:00:00Z","timestamp":1556064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,4,24]],"date-time":"2019-04-24T00:00:00Z","timestamp":1556064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Intraperitoneal administration of antibiotics together with peritoneal dialysis fluids (PDFs) remains the preferable route for treatment of peritoneal dialysis-related peritonitis. For home based therapy, antibiotic-containing PDFs are stored for up to two weeks and warmed up to body-temperature before administration. The present study investigated the compatibility of ciprofloxacin with five commercial PDFs at refrigeration-temperature, room-temperature and body-temperature. Ciprofloxacin concentrations were determined using high-performance liquid chromatography. Drug-diluent stability was evaluated by measurement of pH-values and visual inspection at each sampling point. The antimicrobial activity of ciprofloxacin was assessed by an <jats:italic>E. coli<\/jats:italic> disk diffusion method. Ciprofloxacin was stable at refrigeration-temperature and body-temperature in all PDFs evaluated over the whole study period of 14 days and 24\u2009hours, respectively. At room-temperature, in contrast, ciprofloxacin demonstrated only limited stability in particular when tested in mixed Physioneal. Except for Physioneal 1.36%, no relevant drug adsorption was observed and the antimicrobial activity of ciprofloxacin was found to be preserved in each PDF at each storage condition investigated. Intraperitoneal ciprofloxacin might be used for inpatient and home based therapy of peritoneal dialysis-related peritonitis and no compensatory dose adjustment is needed when stored for up to two weeks at refrigeration-temperature before use.<\/jats:p>","DOI":"10.1038\/s41598-019-42854-y","type":"journal-article","created":{"date-parts":[[2019,4,24]],"date-time":"2019-04-24T10:03:10Z","timestamp":1556100190000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Compatibility of ciprofloxacin with commercial peritoneal dialysis solutions"],"prefix":"10.1038","volume":"9","author":[{"given":"Manuel","family":"Kussmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Ferth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Oberm\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Pichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Zeitlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Wiesholzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Burgmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Poeppl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gottfried","family":"Reznicek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,24]]},"reference":[{"key":"42854_CR1","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3747\/pdi.2016.00078","volume":"36","author":"PK-T Li","year":"2016","unstructured":"Li, P. K.-T. et al. ISPD Peritonitis Recommendations: 2016 Update on Prevention and Treatment. Perit. Dial. Int. 36, 481\u2013508 (2016).","journal-title":"Perit. Dial. Int."},{"key":"42854_CR2","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/089686080902900314","volume":"29","author":"A Davenport","year":"2009","unstructured":"Davenport, A. Peritonitis remains the major clinical complication of peritoneal dialysis: the London, UK, peritonitis audit 2002-2003. Perit. Dial. Int. 29, 297\u2013302 (2009).","journal-title":"Perit. Dial. Int."},{"key":"42854_CR3","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3747\/pdi.2013.00275","volume":"34","author":"S van Esch","year":"2014","unstructured":"van Esch, S., Krediet, R. T. & Struijk, D. G. 32 years\u2019 experience of peritoneal dialysis-related peritonitis in a university hospital. Perit. Dial. Int. 34, 162\u2013170 (2014).","journal-title":"Perit. Dial. Int."},{"key":"42854_CR4","doi-asserted-by":"publisher","first-page":"416","DOI":"10.5414\/CNP75416","volume":"75","author":"S-T Huang","year":"2011","unstructured":"Huang, S.-T. et al. Evolution of microbiological trends and treatment outcomes in peritoneal dialysis-related peritonitis. Clin. Nephrol. 75, 416\u2013425 (2011).","journal-title":"Clin. Nephrol."},{"key":"42854_CR5","doi-asserted-by":"publisher","first-page":"170","DOI":"10.3747\/pdi.2016.00136","volume":"37","author":"SA Zelenitsky","year":"2017","unstructured":"Zelenitsky, S. A. et al. Microbiological Trends and Antimicrobial Resistance in Peritoneal Dialysis-Related Peritonitis, 2005 to 2014. Perit. Dial. Int. 37, 170\u2013176 (2017).","journal-title":"Perit. Dial. Int."},{"key":"42854_CR6","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1177\/089686080702700113","volume":"27","author":"RCS Lima","year":"2007","unstructured":"Lima, R. C. S., Barreira, A., Cardoso, F. L., Lima, M. H. S. & Leite, M. Ciprofloxacin and cefazolin as a combination for empirical initial therapy of peritoneal dialysis-related peritonitis: five-year follow-up. Perit. Dial. Int. 27, 56\u201360 (2007).","journal-title":"Perit. Dial. Int."},{"key":"42854_CR7","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1177\/089686080402400507","volume":"24","author":"E Goffin","year":"2004","unstructured":"Goffin, E. et al. Vancomycin and ciprofloxacin: systemic antibiotic administration for peritoneal dialysis-associated peritonitis. Perit. Dial. Int. 24, 433\u2013439 (2004).","journal-title":"Perit. Dial. Int."},{"key":"42854_CR8","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/BF02001575","volume":"2","author":"A Bauernfeind","year":"1983","unstructured":"Bauernfeind, A. & Peterm\u00fcller, C. In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid. Eur. J. Clin. Microbiol. 2, 111\u2013115 (1983).","journal-title":"Eur. J. Clin. Microbiol."},{"key":"42854_CR9","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1007\/BF02013997","volume":"5","author":"F Follath","year":"1986","unstructured":"Follath, F. et al. Use of ciprofloxacin in the treatment of Pseudomonas aeruginosa infections. Eur. J. Clin. Microbiol. 5, 236\u2013240 (1986).","journal-title":"Eur. J. Clin. Microbiol."},{"key":"42854_CR10","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1177\/089686089501500325","volume":"15","author":"T Gorman","year":"1995","unstructured":"Gorman, T., Eisele, G. & Bailie, G. R. Intraperitoneal antibiotics effectively treat non-dialysis-related infections. Perit. Dial. Int. 15, 283\u2013284 (1995).","journal-title":"Perit. Dial. Int."},{"key":"42854_CR11","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.2215\/CJN.01580407","volume":"2","author":"PP How","year":"2007","unstructured":"How, P. P., Fischer, J. H., Arruda, J. A. & Lau, A. H. Effects of lanthanum carbonate on the absorption and oral bioavailability of ciprofloxacin. Clin. J. Am. Soc. Nephrol. 2, 1235\u20131240 (2007).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"42854_CR12","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1053\/j.ajkd.2003.08.027","volume":"42","author":"MB Kays","year":"2003","unstructured":"Kays, M. B., Overholser, B. R., Mueller, B. A., Moe, S. M. & Sowinski, K. M. Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin. Am. J. Kidney Dis. 42, 1253\u20131259 (2003).","journal-title":"Am. J. Kidney Dis."},{"issue":"Suppl 2","key":"42854_CR13","doi-asserted-by":"crossref","first-page":"S351","DOI":"10.1177\/089686089301302S88","volume":"13","author":"IK Cheng","year":"1993","unstructured":"Cheng, I. K. et al. A randomized prospective comparison of oral versus intraperitoneal ciprofloxacin as the primary treatment of peritonitis complicating continuous ambulatory peritoneal dialysis. Perit. Dial. Int. 13(Suppl 2), S351\u2013354 (1993).","journal-title":"Perit. Dial. Int."},{"key":"42854_CR14","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/089686080902900101","volume":"29","author":"F de Vin","year":"2009","unstructured":"de Vin, F., Rutherford, P. & Faict, D. Intraperitoneal administration of drugs in peritoneal dialysis patients: a review of compatibility and guidance for clinical use. Perit. Dial. Int. 29, 5\u201315 (2009).","journal-title":"Perit. Dial. Int."},{"key":"42854_CR15","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1177\/089686089801800404","volume":"18","author":"IK Cheng","year":"1998","unstructured":"Cheng, I. K. et al. A randomized prospective comparison of oral levofloxacin plus intraperitoneal (IP) vancomycin and IP netromycin plus IP vancomycin as primary treatment of peritonitis complicating CAPD. Perit. Dial. Int. 18, 371\u2013375 (1998).","journal-title":"Perit. Dial. Int."},{"key":"42854_CR16","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1177\/089686080402400509","volume":"24","author":"SM Yeung","year":"2004","unstructured":"Yeung, S. M. et al. Pharmacokinetics of oral ciprofloxacin in continuous cycling peritoneal dialysis. Perit. Dial. Int. 24, 447\u2013453 (2004).","journal-title":"Perit. Dial. Int."},{"key":"42854_CR17","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1128\/AAC.31.11.1787","volume":"31","author":"TA Golper","year":"1987","unstructured":"Golper, T. A., Hartstein, A. I., Morthland, V. H. & Christensen, J. M. Effects of antacids and dialysate dwell times on multiple-dose pharmacokinetics of oral ciprofloxacin in patients on continuous ambulatory peritoneal dialysis. Antimicrob. Agents Chemother. 31, 1787\u20131790 (1987).","journal-title":"Antimicrob. Agents Chemother."},{"key":"42854_CR18","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1093\/jac\/25.5.843","volume":"25","author":"HA Ludlam","year":"1990","unstructured":"Ludlam, H. A. et al. Intraperitoneal ciprofloxacin for the treatment of peritonitis in patients receiving continuous ambulatory peritoneal dialysis (CAPD). J. Antimicrob. Chemother. 25, 843\u2013851 (1990).","journal-title":"J. Antimicrob. Chemother."},{"key":"42854_CR19","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1586\/14787210.4.3.479","volume":"4","author":"F Scaglione","year":"2006","unstructured":"Scaglione, F. & Paraboni, L. Influence of pharmacokinetics\/pharmacodynamics of antibacterials in their dosing regimen selection. Expert Rev. Anti Infect. Ther. 4, 479\u2013490 (2006).","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"42854_CR20","doi-asserted-by":"publisher","first-page":"662","DOI":"10.3747\/pdi.2015.00161","volume":"36","author":"M Kussmann","year":"2016","unstructured":"Kussmann, M. et al. Influence of Different Peritoneal Dialysis Fluids on the In Vitro Activity of Cefepime, Ciprofloxacin, Ertapenem, Meropenem and Tobramycin Against Escherichia Coli. Perit. Dial. Int. 36, 662\u2013668 (2016).","journal-title":"Perit. Dial. Int."},{"key":"42854_CR21","first-page":"2956","volume":"49","author":"WM Mawhinney","year":"1992","unstructured":"Mawhinney, W. M., Adair, C. G., Gorman, S. P. & McClurg, B. Stability of ciprofloxacin in peritoneal dialysis solution. Am. J. Hosp. Pharm. 49, 2956\u20132959 (1992).","journal-title":"Am. J. Hosp. Pharm."},{"key":"42854_CR22","first-page":"373","volume":"51","author":"MP Kane","year":"1994","unstructured":"Kane, M. P., Bailie, G. R., Moon, D. G. & Siu, I. Stability of ciprofloxacin injection in peritoneal dialysis solutions. Am. J. Hosp. Pharm. 51, 373\u2013377 (1994).","journal-title":"Am. J. Hosp. Pharm."},{"key":"42854_CR23","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1177\/089686080002000117","volume":"20","author":"HJ Manley","year":"2000","unstructured":"Manley, H. J. et al. Stability of amphotericin B-lipid complex (Abelcet) in peritoneal dialysis solutions. Perit. Dial. Int. 20, 87\u201390 (2000).","journal-title":"Perit. Dial. Int."},{"key":"42854_CR24","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1159\/000342423","volume":"90","author":"A Burian","year":"2012","unstructured":"Burian, A., Erdogan, Z., Jandrisits, C. & Zeitlinger, M. Impact of pH on activity of trimethoprim, fosfomycin, amikacin, colistin and ertapenem in human urine. Pharmacology 90, 281\u2013287 (2012).","journal-title":"Pharmacology"},{"key":"42854_CR25","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1128\/AAC.36.12.2709","volume":"36","author":"KC Lamp","year":"1992","unstructured":"Lamp, K. C., Rybak, M. J., Bailey, E. M. & Kaatz, G. W. In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin. Antimicrob. Agents Chemother. 36, 2709\u20132714 (1992).","journal-title":"Antimicrob. Agents Chemother."},{"key":"42854_CR26","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/BF01970957","volume":"12","author":"C K\u00f6nig","year":"1993","unstructured":"K\u00f6nig, C., Simmen, H. P. & Blaser, J. Effect of pathological changes of pH, pO2 and pCO2 on the activity of antimicrobial agents in vitro. Eur. J. Clin. Microbiol. Infect. Dis. 12, 519\u2013526 (1993).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"42854_CR27","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1128\/CMR.1.1.54","volume":"1","author":"D Schlessinger","year":"1988","unstructured":"Schlessinger, D. Failure of aminoglycoside antibiotics to kill anaerobic, low-pH, and resistant cultures. Clin. Microbiol. Rev. 1, 54\u201359 (1988).","journal-title":"Clin. Microbiol. Rev."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-42854-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-42854-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-42854-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T09:06:16Z","timestamp":1671267976000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-42854-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,24]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["42854"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-42854-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,24]]},"assertion":[{"value":"7 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"6512"}}